Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M40.9Revenue $M0.1Net Margin (%)-8,583.9Altman Z-Score-37.8
Enterprise Value $M1,083EPS $-0.9Operating Margin %-7,650.6Piotroski F-Score2
P/E(ttm)--Beneish M-Score-7.4Pre-tax Margin (%)-8,700.0Higher ROA y-yN
Price/Book30.010-y EBITDA Growth Rate %-20.4Quick Ratio0.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-42.7Current Ratio0.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-116.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-216.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M6.7ROIC % (ttm)-296.2Gross Margin Increase y-yN

Gurus Latest Trades with NVGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVGNRonald Muhlenkamp 2013-03-31 Sold Out -0.03%$1.84 - $9.05
($3.83)
$ 6.0658%Sold Out0
NVGNRonald Muhlenkamp 2012-12-31 Reduce-0.01%$1.5 - $10.24
($4.96)
$ 6.0622%Reduce 49.15%18,184
NVGNRonald Muhlenkamp 2012-06-30 Buy 0.02%$1.95 - $2.5
($2.26)
$ 6.06168%New holding35,757
NVGNRonald Muhlenkamp 2011-12-31 Reduce-0.01%$0.658 - $1.185
($0.85)
$ 6.06613%Reduce 32.42%35,758
NVGNRonald Muhlenkamp 2011-09-30 Add$0.921 - $2.139
($1.33)
$ 6.06356%Add 4.70%52,915
NVGNRonald Muhlenkamp 2011-06-30 Reduce$1.316 - $2.945
($2.04)
$ 6.06197%Reduce 1.45%50,542
NVGNRonald Muhlenkamp 2011-03-31 Add$0.839 - $3.57
($1.47)
$ 6.06312%Add 1.88%51,287
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVGN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


NVGN: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVGN :

    Quarterly/Annual Reports about NVGN:

      News about NVGN:

      Articles On GuruFocus.com
      Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 
      comment on NVGN Mar 06 2013 

      More From Other Websites
      Novogen to Present at Hong Kong Investor Conference May 17 2015
      Anisina Confirmed as Effective Anti-Cancer Agent in Animal Studies May 13 2015
      Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells May 07 2015
      Novogen Completes the Private Placement of Equity Apr 29 2015
      Novogen Regains Full Compliance with NASDAQ Listing Rule Apr 27 2015
      Novogen Posts Details on Rights Issue Offering for Shareholders Apr 26 2015
      Cantrixil Receives Orphan Drug Designation from FDA Apr 21 2015
      Novogen (NVGN) Stock Falls Today on Private Placement Apr 21 2015
      Novogen taps investors for $30.5m Apr 21 2015
      Novogen Conducts Private Placement and Announces Rights Offering to Shareholders Apr 20 2015
      Novogen poised for capital raising Apr 20 2015
      Cantrixil Highly Successful in Preventing Growth of Chemo-Resistant Ovarian Cancer Apr 20 2015
      Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration Apr 17 2015
      Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer Apr 16 2015
      Novagen (NVGN) Stock Spiked Today on Melanoma Treatment Study Results Apr 09 2015
      Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma Apr 08 2015
      Novogen Engages Leading US Investor Relations Firm Apr 01 2015
      Novogen shares surge on drug data Mar 30 2015
      Yale University and Novogen Release Data on Cantrixil Mode of Action Mar 29 2015
      Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study Mar 18 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK